DCM
PTCT icon

Delpha Capital Management’s PTC Therapeutics PTCT Stock Holding History

Delpha Capital Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-2,851
Closed -$48K – 951
2017
Q4 		$48K Buy
+2,851
New +$48.3K 0.05% 327

Other funds holding PTCT

SCM
Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Delpha Capital Management's PTCT Position: Q1 2018 in Review

Delpha Capital Management sold out of PTC Therapeutics (PTCT) in Q1 2018, closing a stake of 2,851 shares — an estimated $48K sold.

Delpha Capital Management first reported a position in PTCT in Q4 2017 and held it in 1 quarter. The position peaked at $48K in Q4 2017. 148 funds tracked by Wall St. Rank hold PTCT as of Q1 2018.

  • Delpha Capital Management reported no remaining PTC Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Delpha Capital Management sold 2,851 PTC Therapeutics shares in Q1 2018, an estimated $48K.
  • Delpha Capital Management first reported a position in PTC Therapeutics in Q4 2017 and held it in 1 quarter.
  • Delpha Capital Management's PTC Therapeutics position peaked at $48K in Q4 2017.
  • 148 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2018.

Based on Delpha Capital Management's 13F filing for Q1 2018, filed 11 May 2018.